ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
about
Current challenges and novel treatment strategies in double hit lymphomasNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewPutting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy?Ultra-High-Throughput Screening of Natural Product Extracts to Identify Proapoptotic Inhibitors of Bcl-2 Family Proteins.Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.BCL-2 is dispensable for thrombopoiesis and platelet survivalAntagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines.MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cellsHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsSelective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.MCL-1ES induces MCL-1L-dependent BAX- and BAK-independent mitochondrial apoptosis.IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndromeA time to kill: targeting apoptosis in cancer.Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cellsCellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.Intracellular delivery system for antibody-Peptide drug conjugatesHigh-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs AntagonistsTailored fragments of roseophilin selectively antagonize Mcl-1 in vitroProgression and Transformation of Clonally Heterogeneous B-cell Lymphoma.Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1Management of Patients with MYC-Altered Lymphomas.Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.Hematologic malignancies: newer strategies to counter the BCL-2 protein.Cyclin Dependent Kinase 9 Inhibitors for Cancer TherapyA synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected miceHigh efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylationChronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
P2860
Q26770385-D5D1FB77-25BF-4B74-9358-16AFF284324EQ27304386-390CF211-ADFC-4F88-B4D7-ABA24E804B2AQ28085240-DF172CE1-A6D5-4580-BB92-ED07105CFAF2Q30397851-A1752792-A45A-411D-A69E-5431BD3D16F4Q33412553-AA12449C-DAB2-494D-BFE7-7886CF8A2504Q33419789-D0F56F9A-0127-448D-854B-A6320188ED70Q33422077-601DB67D-3591-4202-8E98-24E78F8BB6B7Q33431526-BED61F5E-5920-4FCC-AD11-2DA81B5DA058Q33578868-E0B2C188-D53D-4E19-8982-86E8FDABF5B4Q33823801-4755B135-EA5C-4B59-A889-0FEEF92794A5Q33983255-84DEE8F7-698C-4E07-8A0D-1CC77E873DF9Q34135298-A9BBBDC8-AD9E-4094-BB00-43A3545460AAQ34135333-93E92865-9AAA-4BA6-B7C4-1736791CDC21Q34392488-E0379874-F41C-4A19-B79A-9643B236D82FQ35048595-C7101A6D-8C6B-4F07-A25B-143DBC377D1AQ35130847-1329F232-46F5-4BE3-A5F1-FAF1D9A7ECC9Q35138968-21C3D5FE-1093-46B8-B761-467F41EA0306Q35279393-9586125F-8879-49AE-A0D1-BCDFC9DD1186Q35331086-5031F426-41B6-42C2-95C3-DE7B81CA5746Q35594851-8CC14BF7-33A4-435E-BCD8-4F6D8234B74FQ35634594-9F7BFB05-8F2A-45AA-8D6C-869415343170Q35639894-8146EE1D-97ED-4942-893E-57FB3311E7EEQ35662002-5045B4BD-86C3-497E-8CCE-7F94845338C9Q35809680-519FA685-5E17-4925-9A6D-56398A568B1DQ35920657-80F86861-BC4F-4524-9ABB-D1B31EA78ECBQ35960027-0ABC9171-1A4A-42D4-BC84-2B259AFBA884Q35966191-77DB9043-50AC-4F71-8B1A-48FFE19F73C0Q35979110-11F1980D-D8F6-44E4-8F97-232336B5C6D3Q36015334-8614E10C-CF4D-466A-9F9E-BBD85CC77ACEQ36413780-E6AFABEC-406E-4E2B-BB0A-ABD0610AD4AFQ36426910-12E1F7C0-9C39-4255-B527-CA4B17CDF53EQ36774970-AA62C419-59AA-4560-AF1D-D73D40919930Q37062096-0624F720-3197-427D-98E0-FAE0B1F303FCQ37317447-B7797437-9FEF-4BBB-92DD-DA50E92E3CDDQ37330840-B3AAC719-8603-4475-A4CB-A7C4C2A8E11CQ37347239-CB16632F-D4EF-491F-8EED-E114941F04E6Q37376388-DE8D6F07-BE62-4363-BD87-203841A6CF43Q37416797-67264D58-E6AB-4413-9F03-40B7549D2042Q37676956-213B8869-8D51-443D-B0C1-18F53074129FQ38110472-091294FA-B0C6-4B2C-B7EB-A4095D48E45F
P2860
ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
ABT-199, a new Bcl-2-specific ...... ut provoking thrombocytopenia.
@ast
ABT-199, a new Bcl-2-specific ...... ut provoking thrombocytopenia.
@en
type
label
ABT-199, a new Bcl-2-specific ...... ut provoking thrombocytopenia.
@ast
ABT-199, a new Bcl-2-specific ...... ut provoking thrombocytopenia.
@en
prefLabel
ABT-199, a new Bcl-2-specific ...... ut provoking thrombocytopenia.
@ast
ABT-199, a new Bcl-2-specific ...... ut provoking thrombocytopenia.
@en
P2860
P1433
P1476
ABT-199, a new Bcl-2-specific ...... ut provoking thrombocytopenia.
@en
P2093
Cassandra J Vandenberg
P2860
P304
P356
10.1182/BLOOD-2013-01-475855
P407
P50
P577
2013-01-22T00:00:00Z